|
|
|
Objective: Bruker»ç¿Í Shimadzu»çÀÇ MALDI-TOF MS systemÀ» ÀÌ¿ëÇÏ¿© ¹Ì»ý¹° µ¿Á¤·üÀ» ºñ±³ÇÏ¿´°í ±âÁ¸ phenotypic method ´ëºñ µ¿Á¤ ½Ã°£ ¹× ºñ¿ëÀ» ºñ±³ÇÏ¿´´Ù. |
|
|
Method: ½ºÀ§½ºÀÇ Á¦³×¹Ù ´ëÇк´¿øÀ¸·ÎºÎÅÍ ÃÑ 720°³ÀÇ ±ÕÁÖ¸¦ Á¦°ø ¹Þ¾Æ over-night culture¸¦ ÇÑ µÚ °¢ MS system¿¡¼ ¹Ì»ý¹° µ¿Á¤ ½ÇÇèÀ» ÇÏ°í ±âÁ¸ phenotypic method¿Í ºñ±³ ÇÏ¿´À¸¸ç °á°ú´Â 16S rRNA gene sequencing ¹æ¹ýÀ¸·Î °ËÁõÇÏ¿´´Ù. |
|
|
Result: ÃÑ 720°³ÀÇ isolates¿¡¼ Bruker»çÀÇ MALDI-TOF MS system¿¡¼´Â 680°³, Shimadzu»çÀÇ MALDI-TOF MS system¿¡¼´Â 639°³°¡ high confidence level·Î µ¿Á¤ÀÌ µÇ¾úÀ¸¸ç ±âÁ¸ Phenotypic method ´ëºñ MALDI-TOF MS systemÀ» ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤¹ýÀº ½Ã°£°ú ºñ¿ëÀûÀÎ Ãø¸é¿¡¼ ¸Å¿ì °æÁ¦ÀûÀÎ ¹æ¹ýÀÓÀ» È®ÀÎ ÇÏ¿´´Ù. |
|
|
Conclusion: MALDI-TOF MS systemÀ» ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤¹ýÀº 2¼¼´ë ¹ýÀÎ phenotypic method³ª 3¼¼´ëÀÎ PCR¹æ¹ýµî¿¡ ºñÇÏ¿© ½Ã°£ ¹× ºñ¿ë ¼Ò¸ð°¡ ÀûÀ¸¸ç Á¤È®È÷ µ¿Á¤ ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀÌ´Ù. °¢ MS systemÀ» ºñ±³ ÇÏ¿´À» ¶§ Bruker»çÀÇ MALDI-TOF MS systemÀÌ Shimadzu»çÀÇ MALDI-TOF MS system¿¡ ºñÇÏ¿© Á¶±Ý ´õ ³ôÀº µ¿Á¤·üÀ» ³ªÅ¸³»°í ÀÖ´Ù. |
º´¿ø±ÕÀÇ ºü¸¥ µ¿Á¤Àº ±ÕÀÇ ½Äº° ¹× Ä¡·á¸¦ À§ÇØ ¸Å¿ì Áß¿äÇÏ´Ù. µû¶ó¼ ¿©·¯ ½ÇÇè½Ç¿¡¼ ´õ¿í ºü¸£¸ç °æÁ¦ÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¿Á¤¹ýÀÇ °³¹ß¿¡ Èû¾²°í ÀÖ´Ù. ÃÖ±Ù ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ´Â PCRÀ» ÀÌ¿ëÇÑ µ¿Á¤¹ýÀº À¯ÀüÀÚ ÁõÆøÀ» ÀÌ¿ëÇÏ¿© °³º° À¯ÀüÀÚ¸¦ È®ÀÎÇÏ¿© µ¿Á¤ Çϱ⠶§¹®¿¡ ¸Å¿ì Á¤È®ÇÑ µ¿Á¤¹ýÁß ÇϳªÀÌ´Ù. ÀÌ ¹æ¹ýÀÇ °æ¿ì º°µµÀÇ Àü¹®ÀηÂÀÌ ÇÊ¿ä ÇÏ¸ç º°µµÀÇ ¿©·¯ ½Ã¾à ¹× Àç·á°¡ ÇÊ¿äÇÏ°í DNA¸¦ ÁõÆøÇϴµ¥ ¿À·£ ½Ã°£ÀÌ ¼Ò¸ðµÇ´Â ´ÜÁ¡ÀÌ ÀÖ´Ù. ÀÌ¿¡ ¹ÝÇÏ¿© MALDI-TOF MS systemÀ» ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤ ¹æ¹ýÀº Ãʱâ Àåºñ ±¸ÀÔ ºñ¿ëÀº ±âÁ¸ phenotypic method ȤÀº PCR ¹æ¹ý¿¡ ºñÇÏ¿© °í°¡ÀÌÁö¸¸ ´ÙÀ½°ú °°Àº ÀåÁ¡À» °¡Áö°í ÀÖ´Ù. 1) turn around timeÀÌ ºü¸£´Ù. 2) ÀûÀº¾çÀÇ ½Ã·á·Î ºÐ¼®ÀÌ °¡´ÉÇÏ´Ù. 3) ÇϳªÀÇ »ùÇà ´ç ÀûÀº ºñ¿ëÀ¸·Î µ¿Á¤ÀÌ °¡´ÉÇÏ´Ù.
MS systemÀ» ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤Àº ¹Ì»ý¹°ÀÇ ribosomal proteinÀ» Æ÷ÇÔÇÑ ¹Ì»ý¹° ³»¿¡ dzºÎÇÏ°Ô Á¸ÀçÇÏ´Â ´Ü¹éÁúÀÇ finger printingÀ» ÀÌ¿ëÇØ µ¿Á¤ÀÌ ÀÌ·ç¾î Áø´Ù. ribosomal proteinÀº ¸ðµç ¹Ì»ý¹° Á¾¸¶´Ù °¢±â ´Ù¸¥ ÆÐÅÏÀ» ³ªÅ¸³»¾î °¢ ¹Ì»ý¹°À» Á¾º°·Î ±¸ºÐÀÌ °¡´ÉÇÏ°Ô µÈ´Ù. MALDI-TOF Áú·®ºÐ¼®±â´Â ¸Å¿ì ºü¸£°í Á¤È®ÇÏ°Ô °á°ú¸¦ µµÃâ ÇÒ ¼ö ÀÖ´Â Àåºñ·Î MALDI-TOF MS¸¦ ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤¹ýÀº ¸Å¿ì Á¤È®ÇÏ°Ô µ¿Á¤ÀÌ °¡´ÉÇÏ¸ç ±âÁ¸ phenotypic method ȤÀº PCR ¹æ¹ý¿¡ ºñÇÏ¿© ºü¸£°í Àú·ÅÇÏ°Ô »ç¿ëÀÌ °¡´ÉÇÏ´Ù.
º» ½ÇÇèÀº Bruker»ç¿Í Shimadzu»çÀÇ MS systemÀ» ÀÌ¿ëÇØ ¹Ì»ý¹° µ¿Á¤ ¹× ºñ±³¸¦ ¼öÇàÇÏ¿´À¸¸ç 16S rRNA gene sequencingÀ» ÀÌ¿ëÇÏ¿© °á°ú¸¦ °ËÁõ ÇÏ¿´´Ù. ¶ÇÇÑ MS system°ú ±âÁ¸ ¹æ¹ý°úÀÇ µ¿Á¤ Á¤È®µµ, turnaround time, ºñ¿ëÀ» ºñ±³ÇÏ¿´´Ù.
|
|
|
Harvesting of bacteria for MALDI-TOF MS
¸ðµç ±ÕÀº defined agar medium¿¡¼ over-night ¹è¾çÇÑ ÈÄ Bruker»ç¿Í Shimadzu»çÀÇ MS systemÀ» ÀÌ¿ëÇÏ¿© µ¿Á¤À» ÇÏ¿´´Ù. ¶ÇÇÑ nonselective sheep blood agar¸¦ ÀÌ¿ëÇÏ¿© aerobic bacteria¸¦, CDC anaerobic sheep blood agar¸¦ ÀÌ¿ëÇÏ¿© anaerobic bacteria¸¦, chocolate agar¸¦ ÀÌ¿ëÇÏ¿© Haemophilus spp., ±×¸®°í Karmali ¹èÁö¸¦ ÀÌ¿ëÇÏ¿© Campylobacter¸¦ ¹è¾çÇÏ¿© ¹Ì»ý¹° µ¿Á¤À» ½Ç½ÃÇÏ¿´´Ù. |
|
|
Bruker MALDI-TOF MS system
Over-night Å°¿î Äݷδϸ¦ MALDI target plate¿¡ ¾ã°Ô Æì ¹Ù¸¥ ÈÄ HCCA matrix¸¦ 1.5 ¥ìl¸¦ ¶³¾î¶ß¸°´Ù. »ó¿Â¿¡¼ ¿ÏÀüÈ÷ ±»À» ¶§±îÁö ¸»¸° ÈÄ Bruker»çÀÇ microflex MALDI-TOF MS Àåºñ¿¡ µµÀÔ ÈÄ Biotyper ¼ÒÇÁÆ®¿þ¾î¸¦ ÅëÇÏ¿© µ¿Á¤À» ÇÏ¿´´Ù. Score°ªÀÌ 1.7ÀÌ»óÀº high confidence level·Î °£ÁÖ ÇÏ¿´°í 1.7ÀÌÇÏ´Â ÀçºÐ¼®À» ½Ç½ÃÇÏ¿´À¸¸ç ÀçºÐ¼® °á°úµµ 1.7ÀÌÇÏ¸é µ¿Á¤µÇÁö ¾ÊÀº ±ÕÀ¸·Î ó¸® ÇÏ¿´´Ù.
FIG 1. Illustration of mass spectrum results. Measured mass spectra ranged from 2,000 to 20,000 Da. Extraction of the peaks from the generated mass spectra and their matching against the reference spectra (¡°main spectra¡±) of the integrated database was performed with the MALDI Biotyper software program (Bruker Daltonics). The score value is defined by three components, the matches of the unknown spectrum against the main spectrum, the matches of the main spectrum peaks against the unknown spectrum, and the correlation of intensities of the matched peaks. This leads to a first score from 0 (no match) to 1,000 (perfect identity), which is converted into a log score from 0 to 3. |
|
|
Shimadzu MALDI-TOF MS system
Over-night Å°¿î Äݷδϸ¦ MALDI target plate¿¡ ¾ã°Ô Æì ¹Ù¸¥ ÈÄ matrix¸¦ ¶³¾î¶ß¸®°í °ÇÁ¶ ½ÃŲ µÚ Shimadzu»çÀÇ Axima Assurance system¿¡ µµÀÔÇÑ ÈÄ AnagnosTec»çÀÇ SARAMIS ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¿© ¹Ì»ý¹° µ¿Á¤ ºÐ¼®À» ½Ç½Ã ÇÏ¿´´Ù. SARAMIS ½Ã½ºÅÛÀÇ °æ¿ì¿¡´Â °á°ú°¡ ÆÛ¼¾Æ® °á°ú·Î ³ª¿À°Ô µÇ¸ç 70%ÀÌ»óÀ» high confidence level·Î µ¿Á¤µÇ¾ú´Ù°í ÆÇ´Ü ÇÏ¿´À¸¸ç 70% ÀÌÇÏÀÇ °á°ú´Â ÀçºÐ¼®À» ÇÏ¿´°í 70 % ÀÌÇÏ·Î °°Àº °á°ú°¡ ³ª¿À¸é µ¿Á¤µÇÁö ¾ÊÀº ±ÕÀ¸·Î ó¸® ÇÏ¿´´Ù. |
|
|
Discordant results
Bruker»ç¿Í Shimadzu»çÀÇ MS systemÀ» ÀÌ¿ëÇÑ ¹Ì»ý¹° µ¿Á¤ °á°ú´Â ±âÁ¸ »ýÈÇÐÀûÀÎ ¹æ¹ý°ú ºñ±³ÇÏ¿´À¸¸ç MS system°ú »ýÈÇÐÀûÀÎ ¹æ¹ýÀÌ ÀÏÄ¡ÇÑ °æ¿ì¿¡´Â ÀÏÄ¡ÇÑ Á¾À» Á¤È®ÇÏ°Ô µ¿Á¤µÈ °ÍÀ¸·Î ÆÇ´Ü ÇÏ¿´°í ºÒÀÏÄ¡ ÇÏ´Â °æ¿ì¿¡´Â 16S rRNA sequencing ¹æ¹ýÀ» ÅëÇÏ¿© µ¿Á¤ÇÏ¿´´Ù. 16S rRNA sequencing°ú MS systemÀÇ °á°ú°¡ ´Ù¸¥ °æ¿ì¿¡´Â 16S rRNA sequencing °á°ú¸¦ Âü °ªÀ¸·Î ÆÇ´Ü ÇÏ¿´´Ù. |
|